Unravelling the role of glycogen synthase kinase-3 in Alzheimer’s disease-related epileptic seizures

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Alzheimer’s disease (AD) is the most common form of dementia. An increasing body of evidence describes an elevated incidence of epilepsy in patients with AD, and many transgenic animal models of AD also exhibit seizures and susceptibility to epilepsy. However, the biological mechanisms that underlie the occurrence of seizure or increased susceptibility to seizures in AD is unknown. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that regulates various cellular signaling pathways, and plays a crucial role in the pathogenesis of AD. It has been suggested that GSK-3 might be a key factor that drives epileptogenesis in AD by interacting with the pathological hallmarks of AD, amyloid precursor protein (APP) and tau. Furthermore, seizures may also contribute to the progression of AD through GSK-3. In this way, GSK-3 might be involved in initiating a vicious cycle between AD and seizures. This review aims to summarise the possible role of GSK-3 in the link between AD and seizures. Understanding the role of GSK-3 in AD-associated seizures and epilepsy may help researchers develop new therapeutic approach that can manage seizure and epilepsy in AD patients as well as decelerate the progression of AD.

Original languageEnglish
Article number3676
Number of pages13
JournalInternational Journal of Molecular Sciences
Volume21
Issue number10
DOIs
Publication statusPublished - 2 May 2020

Keywords

  • Alzheimer’s disease
  • Amyloid beta
  • Epileptic seizures
  • Glycogen synthase kinase 3
  • Hyperphosphorylated tau

Cite this